Evidence map›Paper›PMID 42147163›Full record

ArticleResearch square2026

Structural and biochemical insight into allosteric regulation of the human 2-aminoadipic semialdehyde synthase, a bifunctional enzyme involved in lysine catabolism.

Ruoxi Wu, Susmita Khamrui, Tetyana Dodatko, Yufei Xiang, Afrooz Golestanian, Ngoc Dung Pham, Kunal Kumar, Yi Shi, Roman Osman, Robert J DeVita and 2 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruoxi WuDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Susmita KhamruiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Tetyana DodatkoDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Yufei XiangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Afrooz GolestanianDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ngoc Dung PhamDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Kunal KumarDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Yi ShiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Roman OsmanDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Robert J DeVitaDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-2671-8497
Sander M HoutenDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Michael B LazarusDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-6738-2563

Funding

NCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9M
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
NCCAT: National Center for CryoEM Access and TrainingR24GM154192 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI EDWARD T ENG, Jeffrey S Kieft · 2024 to 2026
$21.0M
Chemical and structural tools to study energy homeostasis pathways in cancer and diabetesR35GM124838 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Michael Block Lazarus · 2017 to 2026
$5.2M
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1R01HD112518 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Robert J DeVita, Sander Michel Houten · 2023 to 2026
$2.9M
Targeting succinyl-CoA:glutarate-CoA transferase as a novel therapeutic strategy for glutaric aciduria type 1R01HD118270 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Robert J DeVita, Sander Michel Houten · 2025 to 2026
$1.5M
NCATS NIH HHS UL1 TR004419NICHD NIH HHS R01 HD112518NICHD NIH HHS R01 HD118270NIGMS NIH HHS R24 GM154192NIGMS NIH HHS R35 GM124838NIGMS NIH HHS U24 GM129539
6 · The paper itself

Abstract

Multiple clinically significant inborn errors of metabolism occur in the lysine degradation, even so the regulation of this biochemical pathway remains understudied. The initial rate-limiting step of lysine catabolism is catalyzed by the bifunctional enzyme 2-aminoadipic semialdehyde synthase (AASS). Therefore, understanding the regulation of AASS activity in normal and disease states will be critical for developing novel therapeutic approaches that modulate lysine degradation flux. Here, we report the cryo-EM structure of the full-length 400 kDa tetrameric AASS enzyme complex with substrates and products bound to both the lysine-2-oxoglutarate (LOR) and saccharopine dehydrogenase (SDH) catalytic domains. Our full-length structure shows that two SDH dimers are connected by a long alpha-helix group and flexible loops to a core LOR tetramer. This functional arrangement gives the SDH domain flexibility to move and readily access the products from the LOR domain. Through chemical screens, we also identified allosteric compounds that modulate activity of the AASS. Maleimides, a class of Michael-Addition chemistry substrates, activate the enzyme by reacting with cysteine 414 and shifting the pH optimum for biochemical activity. This observation can be explained mechanistically by pronounced changes in the affinity for NADPH as a function of pH. Remarkably, the mutagenesis of this allosteric Cys414 has dramatic effects on the enzyme's conformation and activity despite being more than 12 Å from the active site. Simulations also show how changes at this distal site can affect the dynamics of the enzyme. Another compound, 1-methylnicotinamide, inhibits the enzyme by catalyzing the formation of a disulfide bond, which was observed through cryo-EM structural studies. Combined, our data indicate that AASS can be modulated at multiple allosteric sites through small molecules providing opportunities to regulate lysine catabolism by either inhibition or activation. Moreover, small changes near the hinge of an enzyme can have large effects on the catalytic properties of the enzyme. Lastly, targeting allosteric cysteines may be a general strategy for modulating enzyme activity by altering the dynamics of the enzyme.

Identifiers

PMID42147163
PMCPMC13174811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.